JDRF International to Support Civica to Manufacture and Distribute Low-Cost Insulin
What has been announced?
JDRF International has joined forces with a number of leading advocacy groups in the United States to provide financial support for Civica Inc., a non-profit generic drug manufacturing company. The project will manufacture and distribute low-cost biosimilar insulin options to enable anyone in the United States to purchase insulin for no more than $30 per vial or $55USD per set of five pens, regardless of insurance status. In the US, insulin can be as expensive as $300USD a vial.
Why is JDRF International choosing this approach?
The support of Civica’s initiative is consistent with our mission: “Improving lives today and tomorrow by accelerating life-changing breakthroughs to cure, prevent, and treat T1D and its complications through research, advocacy, and community engagement.” By making insulin more affordable, people who depend on insulin will be more likely to follow the course of care prescribed by their doctors.
Does this announcement affect Australia?
The announcement has no impact on supply or manufacture of insulin in Australia.
We are fortunate in Australia to have a centralised, Federal system for medicine reimbursement, with substantial existing subsidies and without the complex web of co-pays and rebates that have been driving up insulin prices in the US. Additionally, there is no central program in the US similar to the NDSS (National Diabetes Services Scheme).
How do the costs of insulin compare between Australia and the US?
In the US, a vial of insulin can be as high as $300USD (a little over $400AUD) today. In Australia, once subsidies are taken into account (and not including pre-filled pens) insulin costs $8.50AUD a vial or less.
Is JDRF Australia involved in supporting this initiative?
No. JDRF International (based in the US) is involved.
JDRF Australia welcomes significant commitment to improving lives of Australian type 1 diabetes (T1D) community
Coalition commitment of $273.1M will make technology access a reality for 130,000 Australians living with T1D. JDRF, Australia’s largest organisation dedicated to T1D research and advocacy, welcomes the significant commitment to T1D technology access announced today by Prime Minister Scott Morrison. Currently, many people lose access to this technology, which is shown to improve short- […]
How You Can Help Make Type 1 Diabetes Research a Reality
JDRF has an ambitious vision — a world without type 1 diabetes (T1D). We are the biggest funder of type 1 diabetes research globally and in Australia. In order to achieve this with such a complex autoimmune disease, we must take a strategic, multi-level and collaborative approach to research. JDRF has embarked on an extensive […]
How JDRF’s Advocacy Has Delivered Impact for Type 1 Diabetes
JDRF Australia’s advocacy program exists to support two primary goals. Firstly, to help health policy progress at the same rate as type 1 diabetes (T1D) research, treatments and therapies, so that the type 1 community can access the benefits as soon as possible; and secondly, to secure funding to support JDRF’s research advancements. The program […]
Meet JDRF Advocate, Daniel Webb
This week is National Volunteer Week, where we acknowledge and thank volunteers across Australia for the incredible work they do! We caught up with one of our JDRF volunteers, Daniel Webb, who is involved in JDRF’s Advocacy Program. Why did you decide to join the JDRF advocacy program? I’ve always wanted to be involved with […]
Meet Linda Zanette, JDRF Peer Support Volunteer
This week is National Volunteer Week, where we acknowledge and thank volunteers across Australia for the incredible work they do! We caught up with one of our JDRF volunteers, Linda Zanette, who currently volunteers at JDRF’s Peer Support Program, where she offers support and encouragement to parents of children recently diagnosed with T1D. What drew […]